HIBS is an exchange-traded fund, and — like most leveraged and inverse products — it has no meaningful analyst coverage or consensus price target. Benzinga, MarketBeat, and other data providers list "N/A" or "no recommendations" for the fund, which is typical for instruments designed as short-term trading tools rather than long-term holdings. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Because no analyst-derived target exists, the $23 objective used here reflects publicly discussed technical levels rather than a Wall Street consensus. The $22.64 upper bound of the fund's recent 50-day trading range and a prior resistance zone near $23.23 — a level cited in public chart commentary — provide a realistic, observable price objective. It is important to emphasize that $23 is a technical milestone grounded in market structure, not a forecast or a guarantee.
HIBS was recently changing hands near $19, at the lower end of a 52-week range of roughly $15.00 to $74.95. The fund began 2026 around $50 and has shed roughly 60% of its value year-to-date as high-beta equities rallied, illustrating how punishing a daily-reset inverse fund can be during a strong tape.
Moving from about $19 to $23 implies upside of roughly 20% — a substantial but not extreme move for a fund with this much volatility, yet one that requires a meaningful, sustained pullback in high-beta stocks rather than a single down day. Because the fund resets its -3x leverage daily, the path matters as much as the destination: choppy, sideways markets can erode value even if the underlying index does not trend higher.
The fund's fortunes are essentially the inverse of the market's most aggressive equities. The S&P 500 High Beta Index is heavily weighted toward information technology (roughly 43%), consumer discretionary (about 24%), and financials (about 12%), with names such as NVIDIA, ServiceNow, and semiconductor and solar equipment makers prominent among its constituents.
A rotation out of richly valued, high-beta growth stocks — triggered by, for example, higher-for-longer interest rates, disappointing tech earnings, or a broader risk-off move — would tend to lift HIBS. Its small asset base (around $20 million to $30 million in AUM) also means that relatively modest inflows can amplify short-term price moves.
The most significant obstacle is the prevailing trend itself. High-beta stocks have generally been in an uptrend, and any continuation of that momentum works directly against a -3x inverse fund. Compounding — often called volatility decay — is a structural headwind: even in a flat, choppy market, daily rebalancing can cause the fund to lose value over time.
Additional risks include the fund's elevated net expense ratio (roughly 1.06%), thin liquidity that can produce wider bid-ask spreads, and the inherent danger of holding leveraged inverse products beyond a single trading session. Investors should also remember that HIBS is a tactical trading vehicle, not a buy-and-hold position, and that its long-term record reflects severe losses during bull markets.
From a chart perspective, the area around $22.64 — the recent 50-day range high — represents the first meaningful resistance zone, with a prior resistance level near $23.23 sitting just above it. A decisive move through that band is what would put the $23 objective in play. On the downside, support appears near the low-to-mid $15 area, close to the fund's 52-week low. The broad $15-to-$75 trading range underscores the extreme volatility that makes precise entry and exit timing essential for this product.
Because HIBS has no analyst targets, there is no standardized research horizon attached to the $23 level; technical objectives like this are typically evaluated over days to weeks rather than a full year, reflecting the fund's short-term design. Investors should monitor the direction of the S&P 500's high-beta leaders, major technology earnings, Federal Reserve rate decisions, and inflation data, all of which can drive the sharp swings in sentiment that move this fund. Tracking fund flows and changes in the underlying index's composition can also provide useful signals. From what I see, AI Trend Prediction Engine offers another layer of insight here for spotting potential shifts.
In my view, Tickeron's AI Daily Buy/Sell Signals provides a practical way to stay on top of instruments like this. The tool applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical behavior and market shifts. For a leveraged product such as HIBS, these signals can help identify entry points or flag when conditions are changing, complementing manual analysis without replacing it.
Can HIBS reach $23? The question hinges on whether high-beta equities experience a pullback substantial enough to lift a -3x inverse fund by roughly 20%. The $23 level is a technical objective drawn from public chart discussion, not an analyst consensus, and it sits just above the fund's recent 50-day range high. The path is plausible during a risk-off rotation, but it faces a powerful headwind from the broader uptrend in high-beta growth stocks and the structural erosion of daily-reset leverage. Investors should treat any target for HIBS as a short-term, high-risk proposition and monitor high-beta earnings, interest-rate policy, and market sentiment closely rather than expecting a steady march toward the objective.
One tool I’ve found helpful for this kind of analysis is Tickeron’s AI Daily Buy/Sell Signals. It scans a wide range of securities and highlights potential signals based on AI-driven criteria, which can be useful when evaluating volatile names like HIBS alongside other indicators. I typically review these outputs as one data point among several before making any decisions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
HIBS saw its Momentum Indicator move above the 0 level on October 30, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned positive. In 81 of the 88 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
The Moving Average Convergence Divergence (MACD) for HIBS just turned positive on October 30, 2026. Looking at past instances where HIBS's MACD turned positive, the stock continued to rise in 50 of 52 cases over the following month. The odds of a continued upward trend are 90%.
HIBS moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for HIBS crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 18 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +21.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where HIBS advanced for three days, in 239 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
The Aroon Indicator entered an Uptrend today. In 110 of 121 cases where HIBS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
The 10-day RSI Indicator for HIBS moved out of overbought territory on October 19, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 23 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HIBS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
HIBS broke above its upper Bollinger Band on October 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Category Trading